The identification of epidermal growth factor receptor (EGFR) sensitive mutations in 2004 has emerged as a pivotal factor in the progression of NSCLC and is closely linked to the responsiveness to EGFR‐tyrosine kinase inhibitors (EGFR‐TKIs).3, 4. This evidence concerns the gene EGFR and non-small cell lung carcinoma.